Genome editing, or genome engineering is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Attend this webinar, moderated by Gang Bao, and understand the differences between three technologies.
Hot Topics in Genome Editing: TALEN/CRISPR/ZFN
Thursday, September 6, 2018
11:00 AM EST
Three genome editing technologies have emerged recently that utilize sequence-specific nucleases to facilitate precise genetic modification of a variety of genomes: TALEN (Transcription Activator-Like Effector Nucleases), CRISPR (Clustered, Regularly Interspaced, Short Palindromic Repeats), and ZFN (Zinc Finger Nuclease). All technologies use endonucleases that can be designed to initiate double-strand breaks (DSBs) at virtually any genomic target sequence, and are used for many applications, including gene knockout, transgene knock-in, gene tagging, and correction of genetic defects. While all technologies are becoming more popular, the decision to choose one technology over the other is not always clear.
This moderated discussion will cover:
About the Presenters:
Gang Bao, PhD, is a pioneer in nanomedicine, molecular imaging, and the emerging area of genome editing. The nanoscale structures and devices engineered in his lab have broad-based applications in basic biological research toward the understanding of underlying causes of disease, as well as in the translation of nano-scale tools for disease diagnostics and treatment, such as targeted drug/gene and cell-based therapies. Bao joined Rice University’s Department of Bioengineering in March 2015. In addition to his outstanding track record in basic and translational research as a principal investigator at Johns Hopkins and at the Georgia Institute of Technology and Emory University, he brings two decades of significant experience in the development of leading research and education programs in biomedical engineering. Three multidisciplinary centers, directed by Bao at Georgia Tech, have focused on the detection and treatment of cardiovascular disease, the development of engineered nucleases for treating single-gene disorders such as sickle-cell disease, and pediatric nanomedicine approaches for improving children’s health.
Brian R. Davis, PhD, directs the Center for Stem Cell and Regenerative Medicine at the Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston. He also holds the C. Harold and Lorine G. Wallace Distinguished University Chair. Dr. Davis’ laboratory has as its primary objective sequence-specific genetic correction of mutations in stem cells derived from patients with inherited disorders affecting the lung or blood system, with the ultimate goal of developing stem/progenitor cell-based therapeutic approaches. Over the past five years, his laboratory has developed significant expertise in editing the genome of human pluripotent stem cells – either for correction of inherited genetic mutations or for developing lineage- or stage-specific fluorescent reporters to guide the directed in vitro differentiation of hESCs/hiPSCs to specific cell types of interest. In addition, his laboratory has successfully gene edited human tissue resident stem cells of both the blood and lung systems.
David Segal, PhD, has been a professor of biochemistry and molecular medicine at the University of California, Davis Genome Center since 2014. Research in the Segal lab focuses on the use of gene editing technologies. Dr. Segal has 18 years of experience engineering zinc finger, TALEN and CRISPR/Cas gene editing systems as molecular tools and therapeutics, with more than 80 publications in this field. Dr. Segal has a B.S. in biology from Cornell University, a Ph.D. in Biochemistry from the University of Utah, and was a Postdoctoral Fellow at The Scripps Research Institute in La Jolla, CA.